New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
10:25 EDTCVD, CVD, EBS, EBS, CI, CI, BSX, BSX, BMY, BMY, AMGN, AMGN, ABT, ABT, HNT, HNT, SHPG, SHPG, REGN, REGN, PDCO, PDCO, VRTX, VRTXJPMorgan to host a conference
32nd Annual Healthcare Conference is being held in San Francisco on January 13-16 with webcasted company presentations to begin on January 14 at 10:30 am; not all presentations may be webcasted. Webcast Link
News For CVD;PDCO;REGN;SHPG;HNT;ABT;AMGN;BMY;BSX;CI;EBS;VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 12, 2014
11:17 EDTBMYLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
08:58 EDTCIManaged Care earnings risk low from King vs. Burwell, says Leerink
Leerink believes the Supreme Court decision to the King vs. Burwell case carries low earnings risk for Managed Care companies. The case to determine the legality of Exchange subsidies administered by the Federal Government carries less than 2% and 3% of earnings risk for 2014 and 2015 estimates, respectively, Leerink believes. The firm says Humana (HUM) and Cigna (CI) are currently losing money on Exchanges, and thus could benefit from any Federal Exchange membership loss. Leerink lists Aetna (AET), Centene (CNC), WellPoint (WLP) and Molina Healthcare (MOH) as being most impacted.
08:13 EDTREGNBoston Biotech to hold a conference
Subscribe for More Information
07:43 EDTHNTBarclays to hold a symposium
Subscribe for More Information
07:27 EDTBSXNorth American Spine Society to hold annual meeting
Subscribe for More Information
November 11, 2014
16:14 EDTBMYLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including JAK inhibitors, novel Jakafi combinations for Myelofibrosis and developing compounds on an Analyst/Industry conference call to be held on November 17 at 10 am.
16:05 EDTAMGNAmgen, AstraZeneca say Phase 3 brodalumab study met endpoints
Subscribe for More Information
15:43 EDTBMYLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
12:55 EDTHNT, CIWorkarounds to likely protect insurers from Supreme Court decision, says Wedbush
Subscribe for More Information
10:44 EDTAMGNAmgen reaffirms 2015 adjusted EPS outlook $9.05-$9.40
Subscribe for More Information
10:14 EDTREGNRegeneron data reinforce blockbuster potential of dupilumab, says Piper Jaffray
Piper Jaffray believes the Phase IIb results for dupilumab in patients with moderate to severe asthma reported by Regeneron (REGN) and partner Sanofi (SNY) reinforce the broad potential of the drug in a range of allergic diseases. The firm reiterates its $416 price target and Overweight rating on shares of Regeneron.
05:26 EDTREGNRegeneron, Sanofi announce dupilumab Phase 2b study met primary endpoint
Subscribe for More Information
November 10, 2014
15:54 EDTAMGN, CVDAmerican Society of Nephrology to hold a conference
Subscribe for More Information
15:53 EDTBMYCredit Suisse to hold a conference
Healthcare Conference is being held in Scottsdale, Arizona on November 10-13 with webcasted company presentations to begin on November 11 at 10:30 am; not all company presentations may be webcasted. Webcast Link
07:29 EDTEBSEmergent BioSolutions seeks expanded BioThrax label
Emergent BioSolutions announced that it has submitted a supplemental Biologics License Application to the FDA seeking to expand the label of BioThrax to include a post-exposure prophylaxis indication. BioThrax, the only FDA-licensed vaccine to prevent anthrax disease, is currently licensed for a pre-exposure prophylaxis indication only. The company made a Request for Priority Review Designation to potentially reduce the anticipated approval of this application to six months. The sBLA proposes to expand the BioThrax indication to include a post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure when combined with the recommended course of antimicrobials in persons 18 through 65 years of age. The vaccination schedule consists of three doses of BioThrax administered at 0, 2, and 4 weeks post-exposure.
07:19 EDTREGNCredit Suisse to hold a conference
Subscribe for More Information
06:29 EDTCICigna to restructure HIV prescription drug benefits, WSJ reports
Subscribe for More Information
November 9, 2014
15:45 EDTBMYBristol-Myers announces daclatasvir data from the UNITY trial program
Subscribe for More Information
12:40 EDTBMYBristol-Myers announces data from ALLY trial investigating daclatasvir
Subscribe for More Information
11:45 EDTBMYBristol-Myers announces data from the UNITY trial program
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use